The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadj
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
| Condition(s) | Breast Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings. |
| Who can participate | Inclusion Criteria: * Age ≥18 years or older * HR+/HER2- breast cancer diagnosis based on local standards * Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time * Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP） * Complete medical history was available * Karnofsky Performance Status (KPS) Scale score ≥ 70 Exclusion Criteria: * Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy) * Pregnant or breast-feeding women * Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer * Those who have stage IV breast cance |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Shengjing Hospital |
| Locations | Shenyang, Liaoning, China |
| Start date | 2022-08-01 |
| NCT ID | NCT05263570 |
| Official listing | https://clinicaltrials.gov/study/NCT05263570 |